Unione Europea - italiano - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Italia - italiano - myHealthbox

kedrion - fattore viii della coagulazione del plasma umano - polvere e solvente per soluzione per infusione - 1000 ui/10 ml - antiemorragici, fattore viii della coagulazione del sangue - trattamento e profilassi delle emorragie in pazienti affetti da emofilia a (deficienza congenita di fattore viii). trattamento della deficienza acquisita di fattore viii. trattamento di emofilici con anticorpi contro il fattore viii.

Italia - italiano - myHealthbox

kedrion - fattore viii della coagulazione del plasma umano - polvere e solvente per soluzione per infusione - 500 ui/10 ml - antiemorragici, fattore viii della coagulazione del sangue - trattamento e profilassi delle emorragie in pazienti affetti da emofilia a (deficienza congenita di fattore viii). trattamento della deficienza acquisita di fattore viii. trattamento di emofilici con anticorpi contro il fattore viii.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

octapharma ag - fattore viii coagulationis humanus, proteina - polvere e solvente per soluzione iniettabile - praeparatio cryodesiccata: factor viii coagulationis humanus 250 u.i. corresp. proteina max. 5.5 mg, natrii citras anhydricus, natrii chloridum, calcii chloridum anhydricum, glycinum pro praeparatione corresp. natrium 16.5 mg. solvens: aqua ad iniectabile 5 ml. - emofilia a (carenza congenita di fattore viii), acquisita di fattore viii di mancanza, hemmkörperhämophilie con fattore viii di inibitore - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

octapharma ag - fattore viii coagulationis humanus, proteina - polvere e solvente per soluzione iniettabile - praeparatio cryodesiccata: factor viii coagulationis humanus 500 u.i. corresp. proteina max. 11 mg, natrii citras anhydricus, natrii chloridum, calcii chloridum anhydricum, glycinum pro praeparatione corresp. natrium 33 mg. solvens: aqua ad iniectabile 5 ml. - emofilia a (carenza congenita di fattore viii), acquisita di fattore viii di mancanza, hemmkörperhämophilie con fattore viii di inibitore - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

octapharma ag - fattore viii coagulationis humanus, proteina - polvere e solvente per soluzione iniettabile - praeparatio cryodesiccata: factor viii coagulationis humanus 1000 u.i. corresp. proteina max. 22 mg, natrii citras anhydricus, natrii chloridum, calcii chloridum anhydricum, glycinum pro praeparatione corresp. natrium 33 mg. solvens: aqua ad iniectabile 5 ml. - emofilia a (carenza congenita di fattore viii), acquisita di fattore viii di mancanza, hemmkörperhämophilie con fattore viii di inibitore - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

csl behring ag - fattore xiii - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio sicca: factor xiii 250 u.i. corresp. proteinum humanum 24 - 64 mg, albuminum humanum, glucosum, natrii chloridum, pro vitro. solvens: aqua ad iniectabile 4 ml. - fattore xiii mancanza - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

csl behring ag - fattore xiii - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio sicca: factor xiii 1250 u.i. corresp. proteinum humanum 120-320 mg, albuminum humanum, glucosum, natrii chloridum, pro vitro. solvens: aqua ad iniectabile 20 ml. - fattore xiii mancanza - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

csl behring ag - fattore viii coagulationis humanus - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio cryodesiccata: factor viii coagulationis humanus 500 u.i., natrii chloridum corresp. natrium 11.5 mg, saccharum, calcii chloridum anhydricum, glycinum pro vitro. solvens: aqua ad iniectabile q.s. ad solutionem pro 5 ml. - emofilia a (carenza congenita di fattore viii); fattore viii mancanza - emoderivati

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

csl behring ag - fattore viii coagulationis humanus - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio cryodesiccata: factor viii coagulationis humanus 1000 u.i., natrii chloridum corresp. natrium 23 mg, saccharum, calcii chloridum anhydricum, glycinum pro vitro. solvens: aqua ad iniectabile q.s. ad solutionem pro 10 ml. - emofilia a (carenza congenita di fattore viii); fattore viii mancanza - emoderivati